



Universiteit
Leiden
The Netherlands

The role of inflammation in sciatica: the contradictory effect of macrophages

Djuric, N.

Citation

Djuric, N. (2021, November 4). *The role of inflammation in sciatica: the contradictory effect of macrophages*. Retrieved from <https://hdl.handle.net/1887/3239007>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3239007>

Note: To cite this publication please use the final published version (if applicable).



Chapter 6

Influence of different endplate pathologies on the inflammation profile of herniated discs: a proteomic approach

N. Djuric^{1,2}, S. Rajasekaran³, C. Thangavel¹, M. Raveendran⁴, D.C.R. Soundararajan³,
S.M. Nayagam¹,
M.S. Matchado¹, K.S. Sri Vijay Anand³

¹Ganga Research Centre, No 91, Mettupalayam Road, Coimbatore, 641030, India.

²Department of Neurosurgery, Leiden University Medical Center, Leiden.

³Department of Spine Surgery, Ganga Hospital, 313, Mettupalayam Road, Coimbatore, 641043, India. ⁴Department of Plant Biotechnology, Tamil Nadu Agricultural University, Coimbatore, 641003, India.

Submitted

“He who has a why to live for can bear almost any how”
(Friedrich Nietzsche)

Abstract

Purpose

The aim of this observational radiographic and proteomic study is to explore the influence of both MC and EPA on the inflammation profile of herniated discs using a proteomic and bioinformatics approach.

Methods

15 nuclei pulposi (NP) harvested from surgery underwent LC-MS/MC analysis, the proteome was subsequently scanned for inflammatory pathways using a bioinformatics approach. All proteins that were identified in inflammatory pathways and gene ontology, and present in >7 samples were integrated in a multiple regression analysis with MC and EPA as predictors. Significant proteins were imputed in an interaction and pathway analysis.

Results

Compared to AFT, 6 proteins were significantly altered in EPA: Catalase, Fibrogen beta chain, Protein disulfide-isomerase, Pigment epithelium-derived factor, Osteoprotegerin and lower expression of Antithrombin-III, all of which corresponded to an upregulation of pathways involved in coagulation and detoxification of reactive oxygen species (ROS). Moreover, presence of MC resulted in a significant alteration of 9 proteins compared to patients without MC. Patients with MC showed a significantly higher expression of Clusterin and Lumigan, and lower expression of Catalase, Complement Factor B, Fibrogen beta chain, Protein disulfide-isomerase, Periostin, Alpha-1-antitrypsin and Pigment epithelium-derived factor. Together these alternated protein expressions resulted in a downregulation of pathways involved in detoxification of ROS, complement system and immune system.

Conclusion

Both EPA and MC status significantly influence disc inflammation. The beneficial inflammatory signature of EPA illustrates that endplate pathology does not necessarily have to worsen the outcome, but that the pathological inflammatory state is dependent on the presence of MC.

Introduction

Herniation of the lumbar intervertebral disc is a highly prevalent disease, during which the herniated disc compresses the adjacent nerve root. Patients with herniated discs experience debilitating back pain and often excruciating leg pain that radiates down the dermatome. The severity of these symptoms can vary widely between patients irrespective of the degree of compression. In search for an explanation for this wide variety in symptoms, research has focused on inflammation of the intervertebral disc.

Disc inflammation seems to function as a double-edged sword [1]. In which it shows beneficial effects on one end: For example, through a resorption process of the herniated material initiated by macrophages, which is associated with a faster regression of the disc material [2]. On the other end, inflammation may lead to exacerbation of pain symptoms, through sensitization of the nerve root by pro inflammatory cytokines excreted in the disc [3]. Because of the clinical significance of disc inflammation, it is essential to develop a non-invasive tool that identifies different stages of inflammation.

Recently, there has been an increase in attention for pathology of the endplate, how it may influence the course of the herniation and the rate of recovery. Most research on this topic has focused on vertebral endplate signal changes on MRI, more commonly referred to as Modic changes (MC) [4, 5]. MC represent inflammatory or fibrotic changes in the endplate [6], and have been associated with a slower rate of recovery [7, 8]. This could be explained by intrusion of cartilage pieces of the disrupted endplate in the herniated nucleus pulposus, which subsequently prevent neovascularisation and macrophage infiltration in the disc [9, 10]. Moreover, others have associated MC with detrimental effect of infiltrating macrophages on clinical outcomes [1]. Taken together, the presence of MC seems to be an indication that the type of inflammation has gone from the beneficial type, towards a type of inflammation that may exacerbate pain symptoms and reduce the rate of recovery. However, the current evidence on this is still inconclusive.

A different, relatively underexposed, pathology of the endplate is endplate avulsion. A disc can herniate in two ways: Either through an annulus fibrosus tear (AFT) or through an endplate avulsion (EPA) [11]. During the latter, the annulus fibrosus is torn from the endplate due to a defect of the endplate. This pathology also resulted in pieces of cartilage in the herniated disc but only has a moderate association with MC [11]. At present, it remains unknown whether EPA has similar effects on inflammation of the disc or whether these concepts should be completely separated.

Hence, the aim of this study was to explore the effects of both MC and EPA on the inflammatory signature of the herniated disc using a proteomic and bioinformatics analysis of nucleus pulposus samples.

Materials & Methods

Patient population

IRB approval and informed consent was obtained. 15 nucleus pulposus samples were harvested from patients undergoing discectomy for radicular pain symptoms due to an extruded herniated disc.

Sample Collection

MRI scans were performed pre-surgery by a 1.5 Tesla scanner, and both sagittal T1- and T2-weighted images of the lumbar spine were obtained. Image evaluation of EPA was dichotomized into an intact endplate (AFT group), and an avulsed endplate (EPA group). Evaluation of MC status was according to the criteria of Modic et al [4, 5]. Samples were harvested during surgery, after the removal of the herniated disc material, nucleus pulposus material was separated from annulus fibrosus material and directly transferred to sterile cryopreservation vials, and snap frozen in liquid nitrogen before transport to the research laboratory.

Sample Processing

Around 100 mg Nucleus pulposus tissue from the 15 discs was subjected for extraction of total proteins and subjected to ESI-LC-MS/MS with conditions as described in our earlier report: Rajasekaran S et al., 2017 [12].

Bioinformatics analysis

A detailed description of the bioinformatic analysis and normalisation by spectral count was published earlier: Rajasekaran et al., 2020 [13].

Quantitative analysis

Out of the proteomic database, all proteins with > 2 unique peptide or 1 unique peptide with a PSM \geq 10 were included in the analysis [14]. These selected proteins were subsequently integrated in a Gene Ontology and Pathway enrichment analysis using both STRING and DAVID databases, which allowed us to identify all pathways and protein functions that are involved in inflammatory processes. Moreover, since Mass Spectrometry will regularly fail to detect proteins that are expressed in low quantities, our results will contain a large amount of missing data for the less abundant proteins. Therefore, only proteins that were expressed in at least 8 samples were integrated in the statistical analysis.

Statistical analysis

Data analysis was performed using SPSS software version 25. Effects of EPA and MC status on protein expression were analysed using a multiple regression, for this analysis, protein expression (normalized PSM) was Log₁₀ transformed, Assumptions of normalized residuals, influential cases (cook's distance >1), and homogeneity of variance had to be met. Two-tailed alpha level was set at 0.05. samples with missing values were excluded from the analysis.

Interaction analysis

All significant proteins were integrated in an Interaction analysis using string database. Subsequently, up or down regulations of relevant pathways corresponding to the identified interactions are evaluated.

Results

Patient characteristics

Out of the 15 included patients, 6 patients were characterized as AFT on MRI (Mean age 45.2±19.2 SD, 33% male) and 9 patients as EPA (Mean age 32±5.8 SD, 67% male). Mann Whitney U test showed that neither the difference in age ($p=0.224$) nor sex ($p=0.205$) was significant. Moreover, 8 patients did not show any MC on MRI (Mean age 41.5±17.9 SD, 50% male), and 7 patients did show MC, (Mean age 32.4±5.3 SD, 43% male). Again, the differences in age and sex were not significant. (Age: $p=0.908$, Sex: $p=0.447$). In addition, the distribution of EPA in patients with MC was similar as in patients without MC (Fisher exact: $p=0.608$). Lastly, neither EPA ($p=0.747$), nor MC ($p=0.800$) was associated with the extent of disc degeneration according to classification by Pfirrmann et al [15]. All disc herniations were characterized as the extruded type according to Fardon et al (2014) [16]. An overview of all patient characteristics can be found in table 1.

Pathway analysis

The Gene ontology and Pathway analysis identified 31 pathways that were involved in inflammation related processes (Table S1). In these 31 pathways combined, 147 inflammation related proteins were identified. Out of which 41 were eligible for statistical analysis (Supplementary table S2).

Comparing protein expression

Out of the 41 proteins, 5 proteins were significantly affected by EPA status. EPA patients had significantly higher levels of Catalase (CAT) ($p=0.005$) and FGB ($p=0.007$), Protein disulfide isomerase (P4HB) ($p=0.031$), Pigment Epithelium derived factor (SERPINF1) ($p=0.023$) and Osteoprotegerin (TNFRSF11B) ($p=0.014$), and significantly lower expression of Antithrombin-III (SERPINC1) ($p=0.002$) (Figure 1A, Table 2).

Furthermore, compared to those without MC; MC patients showed significantly higher expression of Clusterin (CLU) ($p=0.019$) and Lumican (LUM) ($p=0.029$), and significantly lower expression of Complement factor B (CFB) ($p=0.022$), (P4HB) ($p=0.029$), Periostin (POSTN) ($p=0.012$) and Alpha-1-antitrypsin (SERPINA1) ($p=0.047$) (Figure 1B). At last, SERPINF1 ($p=0.029$), CAT ($p=0.035$) and FGB ($p<0.001$), which were all upregulated in EPA patients, were downregulated in MC patients (Figure 1B, Table 2).

Interaction analysis

Out of the 6 proteins that were significantly up/downregulated in EPA: CAT, P4HB, FGB and SERPINC1 revealed an interaction. The reactome pathway analysis revealed that this corresponded to an upregulation in: fibrin clot formation and detoxification of reactive oxygen species (ROS). SERPINF1 and TNFR11B did not show direct interactions with any of the other 5 proteins (Figure 2A).

Out of the 7 proteins significantly up- or downregulated in patients with MC, 2 interaction cascades were found. One cascade including CAT, P4HB, SERPINA1, FGB, CFB, and CLU, which were involved in several pathways defined by Reactome.org. Based on whether these proteins were up or downregulated in patients with MC, it could be concluded that the pathways involving Complement/coagulation cascade, detoxification of ROS, and the immune system functions were all downregulated in MC patients. The other interaction cascade, which included POSTN, LUM and SERPINF1, interacted due to often reported co-expression but were not involved in the same pathway (Figure 2B). An overview of the relevant pathways and their involved proteins can be found in Table 3.

Discussion

This study explored the influence of EPA type herniation and MC on the inflammatory signature of the disc. The most important findings of this study are the different effects that the two endplate pathologies have on the inflammation profile. EPA patients showed an upregulation coagulation and detoxification of ROS compared to AFT. By contrast, the detoxification of ROS, complement system and immune system were all downregulated in MC compared to patients without MC.

Coagulation

The increase of coagulation in EPA as compared to AFT was illustrated by an increase in FGB, which is one of the fibrin components necessary for clot formation [17], and a decrease in SERPINC1, a protein that inhibits thrombin activity [18]. The increase in this pathway compared to AFT could be very well explained by the endplate being heavily vascularised, which requires increased coagulation to heal the wound after avulsion. In contrast, in the AFT type, no or little blood vessels are ruptured, and thus upregulation of proteins involved in coagulation is less required. Interestingly, the protein alterations in MC patients suggested a downregulation of coagulation, which was illustrated by a decrease in FGB, and SERPINA1, which has some inhibiting effects on thrombin activity [19]. However, this was accompanied by an increase in CLU, a protein excreted by platelets, of which the exact role remains to be elucidated. Therefore, the current evidence seems insufficient to conclude whether coagulation is downregulated in MC.

Detoxification of reactive oxygen species

Moreover, an EPA type herniation was correlated with an upregulation of detoxification of ROS. This upregulation was illustrated by an increase in P4HB, which functions as a chaperone at high concentrations [20], and an increase in CAT, a protein often excreted by macrophages with anti-oxidative and anti-inflammatory effects while preserving phagocytic and digestive capacities [21, 22]. In contrast, when comparing patients with MC to those without MC: CAT and P4HB were down regulated, and consequently detoxification of ROS was also downregulated.

From a clinical perspective, the upregulation of ROS detoxification illustrates an increase of 'beneficial inflammation' in avulsed endplate herniations as compared to the annular tear type. This increase of beneficial inflammation could be explained by the increased exposure to neovascularisation from the highly vascularised endplate [23]. Unfortunately, not all herniated material can be absorbed in equal efficiency. This depends on the amount of cartilage pieces, and the quantity and functionality of the immune cells [9, 22]. Such an inadequately absorbed herniation may stimulate nucleus pulposus cells to induce a chronic inflammation process [24, 25], characterized by an increase in pro-inflammatory cytokines, reactive oxygen and fibrotic changes [6, 26]. This chronic inflammation process can be identified on the MRI as MC [6], and can explain the reduced recovery rate.

Immune system

In line with the immune-modulating effects of CAT, SERPINA1 is also known for its immune-modulating capacity. The expression of this protein is increased by immune cells during an inflammatory response to balance the pro-inflammatory cytokines and oxidative stress [27]. In addition, it has been shown to switch the type of microglia activity away from oxidative stress and pro-inflammatory cytokines towards tissue remodelling and phagocytosis [28, 29]. The lower expression of SERPINA1 in MC patients compared to those without MC thus suggest an alteration in the type of infiltrating immune cells.

Also in line with the altered immune cell infiltration in MC patients, is the downregulation of the complement system in MC, illustrated by a significant decrease in CFB, and an almost significant decrease in C3. This was accompanied by an increase in CLU, which is an inhibitor of the complex system cascade [30]. Moreover, together with the decrease in the detoxification of ROS, a downregulation of immune response may together indicate a malfunctioning immune response. This may create opportunities for subclinical infections with anaerobic bacteria, which is in line with the emerging evidence that MC is associated with bacterial infections [31, 32].

Tissue resorption

In addition to the inflammatory pathways, the alterations in protein expression also illustrated differences in tissue resorption. In MC patients, SERPINF1 was downregulated, illustrating a deficiency in cartilage clearance, which is, again, in line with the reduced recovery rate associated with MC [8]. This cartilage clearance was also confirmed by the decrease in MC of POSTN, a protein participating in post-injury tissue regeneration processes, during which, it stimulated degradation of ECM through upregulation of matrix metalloproteases [33]. LUM belongs to the family of small-leucine rich proteins, which could get accumulated as a part of healing response as its increased expression has been documented in fibrotic lesions previously secondary to stimulation from inflammatory molecules such as TNF-A. Lumican has also been shown to modulate host response and play an important role activation of an innate immune mechanisms in response to bacterial lipopolysaccharides (LPS) and other pathogen associated molecular patterns [34]. Further LUM has been documented to have an important role in inflammatory bowel diseases such as colitis and is believed to promote intestinal homeostasis by aiding innate immune and inflammatory responses [35]. The accumulation of LUM in MC in this study adds evidence to a pro-inflammatory status in these discs which get activated probably due to infective aetiology.

As this was the first study to compare protein expression between AFT and EPA, no comparisons with previous literature could be made. Regarding MC, even though our study found a great variety of proteins involved in inflammation, none of the proteins reported by Dudli et al. (2017) were found in our analysis [6]. This can be explained by proteomics being less sensitive than a gene expression method, which prevents it from detecting proteins that are expressed in low quantities reported in previous studies [6, 7, 36, 37]. Nevertheless, similar to our results, Dudli et al (2017) also showed that only a limited amount of proteins were altered, thereby indicating that the differences are rather subtle [6]. Another limitation of this study is the limited sample size and absence of correction for multiple testing. These results should therefore be interpreted as high-grade evidence, but instead as a starting point for more extensive research on the newly identified proteins and pathways outlined in this paper.

In summary, the proteomic inflammatory signature of AFT and EPA patients differed significantly, with EPA illustrating an increase in a beneficial inflammatory response. With regard to MC, those with MC showed a shift away from beneficial and likely towards detrimental inflammatory response. Taken together, the evidence presented in this paper portrays that endplate pathology does not necessarily lead to reduced recovery, but that the presence of MC illustrates a shift in the inflammatory proteome that makes spontaneous resorption less likely. Future studies should focus on validating these findings in a large study cohort, and preferably integrate a cytokine assay and immune cell staining analysis.

Acknowledgement

We thank Ms. Alishya Maria Jose for her help in sample collection and data maintenance and Ms. Sujitha M of Aravind Medical Research Foundation for LC-MS/MS acquisitions.

Bibliography

1. Djuric N, Yang X, Ostelo R et al, *Disc inflammation and Modic changes show an interaction effect on recovery after surgery for lumbar disc herniation*. Eur Spine J, 2019. 28(11): p. 2579-2587.
2. Doita M, Kanatani T, Ozaki T et al, *Influence of macrophage infiltration of herniated disc tissue on the production of matrix metalloproteinases leading to disc resorption*. Spine (Phila Pa 1976), 2001. 26(14): p. 1522-7.
3. Cuellar JM, Golish SR, Reuter MW et al, *Cytokine evaluation in individuals with low back pain using discographic lavage*. Spine J, 2010. 10(3): p. 212-8.
4. Modic MT, Masaryk TJ, Ross JS et al, *Imaging of degenerative disk disease*. Radiology, 1988. 168(1): p. 177-86.
5. Modic MT, Steinberg PM, Ross JS et al, *Degenerative disk disease: assessment of changes in vertebral body marrow with MR imaging*. Radiology, 1988. 166(1 Pt 1): p. 193-9.
6. Dudli S, Sing DC, Hu SS et al, *ISSLS PRIZE IN BASIC SCIENCE 2017: Intervertebral disc/bone marrow cross-talk with Modic changes*. Eur Spine J, 2017. 26(5): p. 1362-1373.
7. Shan Z, Fan S, Xie Q et al, *Spontaneous resorption of lumbar disc herniation is less likely when modic changes are present*. Spine (Phila Pa 1976), 2014. 39(9): p. 736-44.
8. Ding L, Teng X, Fan S et al, *The Association Between Modic Changes of Lumbar Endplates and Spontaneous Absorption of Herniated Intervertebral Discs*. Cell Biochem Biophys, 2015. 71(3): p. 1357-63.
9. Kawaguchi K, Harimaya K, Matsumoto Y et al, *Effect of cartilaginous endplates on extruded disc resorption in lumbar disc herniation*. PLoS One, 2018. 13(4): p. e0195946.
10. Lama P, Zehra U, Balkovec C et al, *Significance of cartilage endplate within herniated disc tissue*. Eur Spine J, 2014. 23(9): p. 1869-77.
11. Rajasekaran S, Bajaj N, Tubaki V et al, *ISSLS Prize winner: The anatomy of failure in lumbar disc herniation: an in vivo, multimodal, prospective study of 181 subjects*. Spine (Phila Pa 1976), 2013. 38(17): p. 1491-500.
12. Rajasekaran S, Tangavel C, Aiyer SN et al, *ISSLS PRIZE IN CLINICAL SCIENCE 2017: Is infection the possible initiator of disc disease? An insight from proteomic analysis*. Eur Spine J, 2017. 26(5): p. 1384-1400.
13. Rajasekaran S, Tangavel C, Djuric N et al, *Part 1: profiling extra cellular matrix core proteome of human fetal nucleus pulposus in search for regenerative targets*. Sci Rep, 2020. 10(1): p. 15684.
14. Higdon R and Kolker E, *A predictive model for identifying proteins by a single peptide match*. Bioinformatics, 2007. 23(3): p. 277-80.
15. Pfirrmann CW, Metzdorf A, Zanetti M et al, *Magnetic resonance classification of lumbar intervertebral disc degeneration*. Spine (Phila Pa 1976), 2001. 26(17): p. 1873-8.
16. Fardon DF, Williams AL, Dohring EJ et al, *Lumbar disc nomenclature: version 2.0: recommendations of the combined task forces of the North American Spine Society, the American Society of Spine Radiology, and the American Society of Neuroradiology*. Spine (Phila Pa 1976), 2014. 39(24): p. E1448-65.
17. Flood VH, Al-Mondhiry HA, and Farrell DH, *The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance*. Br J Haematol, 2006. 134(2): p. 220-6.
18. Zeng W, Hu B, Tang L et al, *Recurrent mutations in a SERPINC1 hotspot associate with venous thrombosis without apparent antithrombin deficiency*. Oncotarget, 2017. 8(48): p. 84417-84425.
19. Talens S, Malfliet JJ, van Hal PT et al, *Identification and characterization of alpha1 -antitrypsin in fibrin clots*. J Thromb Haemost, 2013. 11(7): p. 1319-28.

20. Lumb RA and Bulleid NJ, *Is protein disulfide isomerase a redox-dependent molecular chaperone?* *Embo j*, 2002. 21(24): p. 6763-70.
21. Zhou Z, Su Y, and Fa XE, *Isorhynchophylline exerts anti-inflammatory and anti-oxidative activities in LPS-stimulated murine alveolar macrophages.* *Life Sci*, 2019. 223: p. 137-145.
22. Vida C, de Toda IM, Cruces J et al, *Role of macrophages in age-related oxidative stress and lipofuscin accumulation in mice.* *Redox Biol*, 2017. 12: p. 423-437.
23. Hee HT, Chuah YJ, Tan BH et al, *Vascularization and morphological changes of the endplate after axial compression and distraction of the intervertebral disc.* *Spine (Phila Pa 1976)*, 2011. 36(7): p. 505-11.
24. Yang H, Liu H, Li X et al, *TNF-alpha and TGF-beta1 regulate Syndecan-4 expression in nucleus pulposus cells: role of the mitogen-activated protein kinase and NF-kappaB pathways.* *Connect Tissue Res*, 2015. 56(4): p. 281-7.
25. Mouser VHM, Arkesteijn ITM, van Dijk BGM et al, *Hypotonicity differentially affects inflammatory marker production by nucleus pulposus tissue in simulated disc degeneration versus herniation.* *J Orthop Res*, 2019. 37(5): p. 1110-1116.
26. Wynn TA, *Cellular and molecular mechanisms of fibrosis.* *J Pathol*, 2008. 214(2): p. 199-210.
27. Boskovic G and Twining SS, *Local control of alpha1-proteinase inhibitor levels: regulation of alpha1-proteinase inhibitor in the human cornea by growth factors and cytokines.* *Biochim Biophys Acta*, 1998. 1403(1): p. 37-46.
28. Martinez FO and Gordon S, *The M1 and M2 paradigm of macrophage activation: time for reassessment.* *F1000Prime Rep*, 2014. 6: p. 13.
29. Zhou T, Huang Z, Zhu X et al, *Alpha-1 Antitrypsin Attenuates M1 Microglia-Mediated Neuroinflammation in Retinal Degeneration.* *Front Immunol*, 2018. 9: p. 1202.
30. Ghiso J, Matsubara E, Koudinov A et al, *The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex.* *Biochem J*, 1993. 293 (Pt 1): p. 27-30.
31. Albert HB, Sorensen JS, Christensen BS et al, *Antibiotic treatment in patients with chronic low back pain and vertebral bone edema (Modic type 1 changes): a double-blind randomized clinical controlled trial of efficacy.* *Eur Spine J*, 2013. 22(4): p. 697-707.
32. Jiao Y, Lin Y, Zheng Y et al, *The bacteria-positive proportion in the disc tissue samples from surgery: a systematic review and meta-analysis.* *Eur Spine J*, 2019. 28(12): p. 2941-2950.
33. Conway SJ, Izuhara K, Kudo Y et al, *The role of periostin in tissue remodeling across health and disease.* *Cell Mol Life Sci*, 2014. 71(7): p. 1279-88.
34. Pilling D, Vakil V, Cox N et al, *TNF-alpha-stimulated fibroblasts secrete lumican to promote fibrocyte differentiation.* *Proc Natl Acad Sci U S A*, 2015. 112(38): p. 11929-34.
35. Lohr K, Sardana H, Lee S et al, *Extracellular matrix protein lumican regulates inflammation in a mouse model of colitis.* *Inflamm Bowel Dis*, 2012. 18(1): p. 143-51.
36. Schistad EI, Espeland A, Pedersen LM et al, *Association between baseline IL-6 and 1-year recovery in lumbar radicular pain.* *Eur J Pain*, 2014. 18(10): p. 1394-401.
37. Dudli S, Miller S, Demir-Deviren S et al, *Inflammatory response of disc cells against Propionibacterium acnes depends on the presence of lumbar Modic changes.* *Eur Spine J*, 2017.

Appendix

Table 1. Patients characteristics

| Case ID | Age | Sex | Pfirmann | MC | AFT/EPA |
|---------|-----|-----|----------|--------|---------|
| 1 | 29 | F | 3 | no | AFT |
| 3 | 70 | F | 5 | no | AFT |
| 5 | 45 | M | 3 | no | AFT |
| 6 | 67 | F | 3 | no | AFT |
| 7 | 27 | M | 3 | no | EPA |
| 8 | 26 | M | 4 | no | EPA |
| 9 | 40 | M | 3 | no | EPA |
| 10 | 28 | M | 4 | no | EPA |
| 11 | 29 | F | 4 | type 1 | EPA |
| 12 | 34 | M | 4 | type 2 | AFT |
| 13 | 26 | F | 4 | type 2 | AFT |
| 14 | 32 | M | 4 | type 2 | EPA |
| 15 | 43 | F | 4 | type 2 | EPA |
| 16 | 31 | M | 3 | type 2 | EPA |
| 17 | 32 | F | 2 | type 2 | EPA |

Patient characteristics at baseline, age, sex, Disc degeneration (Pfirmann grade), AFT/EPA- and MC status are displayed for all patients.

Table 2. Effect of AFT/EPA and MC status on protein expression

| Protein Gene symbol | N (AFT/EPA) | Beta (P-value) AFT vs EPA | N (no MC/MC) | Beta (P-value) no MC vs MC |
|---------------------|-------------|------------------------------|--------------|-------------------------------|
| A1BG | 5/5 | -0.021 ±0.171 (0.907) | 6/4 | -0.216 ±0.175(0.258) |
| A2M | 6/9 | 0.119 ±0.296 (0.696) | 8/7 | -0.366 ±0.291 (0.232) |
| ACTB | 2/7 | -0.077 ±0.221 (0.739) | 5/4 | -216 ±0.185 (0.285) |
| AGT | 3/8 | 0.094 ±0.197 (0.647) | 6/5 | -0.214 ±0.176(0.258) |
| ANXA2 | 6/8 | 0.089 ±0.157 (0.584) | 8/6 | -0.306 ±0.157 (0.077) |
| APOA1 | 5/7 | -0.184 ±0.209 (0.401) | 6/6 | 0.373 ±0.206 (0.104) |
| C3 | 6/9 | -0.077 ±0.131 (0.565) | 8/7 | -0.269 ±0.129 (0.058) |
| C5 | 4/5 | -0.427 ±0.193 (0.077) | 6/3 | 0.164 ±0.215(0.480) |
| CA1 | 6/6 | -0.081 ±0.146 (0.591) | 6/6 | 0.269 ±0.144 (0.094) |
| CA2 | 6/2 | 0.236 ±0.292 (0.456) | 2/6 | 0.064 ±0.337 (0.856) |
| CAT | 5/7 | 0.393 ±0.105 (0.005)** | 6/6 | -0.257 ±0.103 (0.035)* |
| CFB | 6/7 | 0.235 ±0.156 (0.163) | 8/5 | -0.434 ±0.160 (0.022)* |
| CLU | 6/9 | 0.031 ±0.067 (0.649) | 8/7 | 0.177 ±0.066 (0.019)* |
| COL2A1 | 6/8 | 0.124 ±0.296 (0.684) | 7/7 | 0.038 ±0.289(0.897) |
| FGB | 5/6 | 0.385 ±0.097 (0.007)** | 5/6 | -0.72 ±0.097 (<0.001)** |
| FGG | 6/8 | 0.163 ±0.211 (0.455) | 8/6 | -.347 ±0.211 (0.128) |
| FN1 | 6/9 | 0.144 ±0.093 (0.146) | 8/7 | -0.084 ±0.091 (0.373) |
| GAPDH | 6/9 | 0.048 ±0.129 (0.717) | 8/7 | -0.100 ±0.126 (0.446) |
| GSN | 6/9 | 0.065 ±0.194 (0.742) | 8/7 | -0.292 ±0.190 (0.151) |
| HBB | 6/9 | -0.016 ±0.132 (0.907) | 8/7 | 0.098 ±0.130 (0.467) |
| HP | 6/9 | -0.058 ±0.169 (0.736) | 8/7 | -0.82 ±0.629 (0.629) |
| HPX | 6/8 | -0.038 ± 0.150 (0.807) | 8/6 | -0.120 ±0.150 (0.441) |
| HSPG2 | 5/3 | 0.051 ±0.322 (0.880) | 4/4 | 0.087 ±0.312 (0.792) |
| HTRA1 | 6/9 | -0.186 ±0.151 (0.243) | 8/7 | 0.178 ±0.148 (0.253) |
| KRT1 | 6/9 | 0.167 ±0.105 (0.138) | 8/7 | -0.077 ±0.103 (0.469) |
| KRT16 | 3/7 | 0.19 ±0.151 (0.249) | 4/6 | -0.101 ±0.141 (0.498) |
| KRT6A | 2/6 | 0.162 ±0.168 (0.381) | 4/4 | 0.025 ±.146 (0.868) |
| LUM | 6/9 | 0.061 ±0.075 (0.431) | 8/7 | 0.183 ±0.074 (0.029)* |
| LYZ | 6/5 | -0.207 ±0.156 (0.220) | 5/6 | 0.031 ±0.156 (0.848) |
| P4HB | 5/5 | 0.507 ±0.189 (0.031)* | 6/4 | -0.439 ±0.193 (0.038)* |
| PKM | 4/4 | 0.098 ±0.268 (0.730) | 3/5 | -0.571 ±0.277 (0.094) |
| POSTN | 6/6 | -0.291 ±0.205 (0.120) | 7/5 | -0.650 ±0.208 (0.012)* |
| PRG4 | 4/9 | -0.286 ±212(0.207) | 7/6 | 0.138 ±0.197 (0.500) |
| SERPINA1 | 6/9 | -0.014 ±0.088 (0.875) | 8/7 | -0.192 ±0.087 (0.047)* |
| SERPINC1 | 5/6 | -0.629 ±0.135 (0.002)** | 6/5 | 0.105 ±0.135 (0.460) |
| SERPINF1 | 6/8 | 0.527 ±0.200 (0.023)* | 7/7 | -0.499 ±0.198 (0.029)* |
| SERPING1 | 6/8 | 0.035 ±0.159(0.831) | 8/6 | -0.274 ±0.159 (0.112) |
| THBS1 | 5/7 | -0.081 ±0.225 (0.726) | 7/5 | -0.118 ±0.225(0.614) |

| Protein Gene symbol | N (AFT/EPA) | Beta (P-value) AFT vs EPA | N (no MC/MC) | Beta (P-value) no MC vs MC |
|---------------------|-------------|------------------------------|--------------|-------------------------------|
| TNFRSF11B | 5/4 | 0.289 ±0.084 (0.014)* | 5/4 | -0.044 ±0.084 (0.620) |
| VIM | 5/5 | -0.117 ±0.256 (0.660) | 6/4 | -0.446 ±0.261 (0.117) |
| VTN | 3/9 | -0.215 ±0.260 (0.430) | 6/6 | -0.056 ±0.225 (0.810) |

Table 2 displays the results of the multiple regression analysis in which EPA and MC status were used as predictor for the listed protein expression. Beta ±SE and p-values are given, * indicates P<0.05, ** indicates P<0.01.

Table 3. Up/down regulation of pathways in EPA vs AFT and MC vs no MC

| A | | | |
|---|---------|------------------------------------|---------------|
| EPA pathways interaction analysis | P-value | Matching proteins | Change in EPA |
| Common Pathway of Fibrin Clot Formation | 0.0012 | FGB ,SERPINC1 | upregulated |
| Detoxification of Reactive Oxygen Species | 0.0015 | CAT,P4HB | upregulated |
| Immune System | 0.0114 | CAT,FGB,P4HB,TNFRSF11B | inconclusive |
| B | | | |
| MC pathways interaction analysis | P-value | Matching proteins | Change in MC |
| Platelet degranulation | 0.0018 | CLU, FGB, SERPINA1 | downregulated |
| Detoxification of Reactive Oxygen Species | 0.0020 | CAT, P4HB | downregulated |
| Regulation of Complement cascade | 0.0025 | CFB, CLU | downregulated |
| Immune System | 0.0018 | CAT, CFB, CLU, FGB, P4HB, SERPINA1 | downregulated |

Table 3 shows the reactome pathways in which the significant up or downregulated proteins are involved. **3A** shows the pathway results of the 6 proteins that were altered in EPA, **3B** shows the pathway results of the 9 proteins that were altered in MC. The first column describes the name of the pathway, the second the p-value of the enrichment of the pathway provided by reactome, the third column lists the proteins that were picked up in the respective pathway, and the last column shows whether the pathway is up or downregulated in EPA(3A) / MC(3B). The up or down regulation of the pathway was based on the up/downregulation of the involved proteins combined with their specific role in the pathway (stimulating or inhibiting the pathway. Change in a pathway is scored inconclusive when both stimulatory- and inhibitory proteins are upregulated, and thus no clear up or downregulation could be identified.

Figure 1. Significantly altered protein expression




Figure 1 illustrates the significantly different expressed proteins between AFT vs EPA and no MC vs MC, as assessed by a multiple regression with EPA and MC status as predictor. Figure **1A** shows the 7 proteins that differed significantly between AFT and EPA. AFT is used as baseline to illustrate the Log₂ fold changes in EPA as compared to AFT, all proteins symbols are shown on the X axis, Log₂ fold changes in protein expression (nPSM) are shown on the Y axis. Figure **1B** displays the 9 proteins significantly altered in MC compared to no MC. No MC is used as baseline to show the Log₂ fold changes in MC compared to no MC. all proteins symbols are shown on the X axis, Log₂ fold changes in protein expression (nPSM) are shown on the Y axis.

Figure 2. Protein-protein interaction analysis by STRING database




Figure 2 illustrates the protein-protein interactions revealed by STRING database between AFT vs EPA and no MC vs MC, as assessed by a multiple regression with EPA and MC status as predictor. Figure 2A shows the interactions between the proteins that were significantly up or down regulated in EPA compared to AFT. Lines between the proteins illustrate a direct functional interaction between the two proteins, with either a stimulating or inhibiting effect, which connects 4 out of the 6 proteins in an interaction cascade. Arrows indicate up or downregulation in EPA compared to AFT. Figure 2B shows the interactions between the proteins that were significantly up or down regulated in patients with MC compared to those without. Lines between the proteins illustrate a direct functional interaction between the two proteins, with either a stimulating or inhibiting effect, which results in 2 interaction cascades, one with 6 and one with 3 out of the 9 proteins. Arrows indicate up or downregulation in MC compared to no MC.

Supplementary Appendix

Table S1. Identification of Inflammation related pathways in the total NP proteome

| Pathway | P-value | Proteins identified |
|--|----------|---------------------|
| leukocyte mediated immunity | 2,76E-30 | 57 |
| immune effector process | 1,46E-26 | 39 |
| immune response | 5,48E-26 | 79 |
| neutrophil degranulation | 1,86E-22 | 52 |
| myeloid leukocyte activation | 4,99E-21 | 71 |
| myeloid leukocyte activation | 4,99E-21 | 56 |
| leukocyte activation involved in immune response | 1,97E-20 | 8 |
| regulation of complement activation | 2,85E-20 | 23 |
| complement activation | 1,73E-19 | 22 |
| regulation of humoral immune response | 3,96E-19 | 24 |
| regulation of acute inflammatory response | 6,42E-18 | 25 |
| complement activation, classical pathway | 7,18E-17 | 18 |
| regulation of inflammatory response | 1,13E-13 | 35 |
| regulation of immune response | 4,38E-13 | 55 |
| activation of immune response | 1,12E-12 | 36 |
| positive regulation of immune system process | 2,32E-11 | 52 |
| regulation of immune effector process | 3,04E-10 | 31 |
| complement activation, alternative pathway | 2,97E-09 | 9 |
| innate immune response | 9,44E-09 | 31 |
| acute inflammatory response | 1,23E-07 | 13 |
| inflammatory response | 1,31E-07 | 101 |
| antimicrobial humoral response | 1,36E-07 | 17 |
| adaptive immune response | 7,99E-07 | 22 |
| interleukin-12-mediated signaling pathway | 8,37E-05 | 40 |
| toll-like receptor signaling pathway | 0,00013 | 10 |
| positive regulation of apoptotic cell clearance | 0,00035 | 4 |
| regulation of transforming growth factor beta receptor signaling pathway | 0,00043 | 10 |
| antimicrobial humoral immune response mediated by antimicrobial peptide | 0,00055 | 10 |
| negative regulation of immune system process | 0,0088 | 18 |
| positive regulation of cytokine production | 0,0089 | 17 |
| positive regulation of NF-kappaB transcription factor activity | 0,0114 | 9 |

Table S1 lists all the pathways and gene ontology processes from DAVID and STRING database related to inflammation, which were found in the total NP proteome. Proteins involved in these pathways were subsequently included in the study analysis. The name of the pathway is listed in the first column, the second column provides the p-value of the pathway/process enrichment, the 3th column shows the nr. of proteins of that pathway that were present in the study sample.

Table S2. List of protein names and gene their corresponding gene symbols

| Gene Symbol | Protein Name |
|-------------|--|
| A1BG | Alpha-1B-glycoprotein |
| A2M | Alpha-2-macroglobulin |
| ACTB | Actin, cytoplasmic 1 |
| AGT | Angiotensinogen |
| ANXA2 | Annexin A2 |
| APOA1 | Apolipoprotein A-I |
| C3 | Complement C3 |
| C5 | Complement C5 |
| CA1 | Carbonic anhydrase 1 |
| CA2 | Carbonic anhydrase 2 |
| CAT | Catalase |
| CFB | Complement factor B |
| CLU | Clusterin |
| COL2A1 | Collagen alpha-1(II) chain |
| FGB | Fibrinogen beta chain |
| FGG | Fibrinogen gamma chain |
| FN1 | Fibronectin |
| GAPDH | Glyceraldehyde-3-phosphate dehydrogenase |
| GSN | Gelsolin |
| HBB | Hemoglobin subunit beta |
| HP | Haptoglobin |
| HPX | Hemopexin |
| HSPG2 | Basement membrane-specific heparan sulfate proteoglycan core protein |
| HTRA1 | Serine protease HTRA1 |
| KRT1 | Keratin, type II cytoskeletal 1 |
| KRT16 | Keratin, type I cytoskeletal 16 |
| KRT6A | Keratin, type II cytoskeletal 6A |
| LUM | Lumican |
| LYZ | Lysozyme C |
| P4HB | Protein disulfide-isomerase |
| PKM | Pyruvate kinase |
| POSTN | Periostin |
| PRG4 | Proteoglycan 4 |
| SERPINA1 | Alpha-1-antitrypsin |
| SERPINC1 | Antithrombin-III |
| SERPINF1 | Pigment epithelium-derived factor |
| SERPING1 | Plasma protease C1 inhibitor |
| THBS1 | Thrombospondin-1 |
| TNFRSF11B | Tumor necrosis factor receptor superfamily member 11B; Osteoprotegerin |
| VIM | Vimentin |
| VTN | Vitronectin |

Table S2 lists the proteins from the inflammation related pathways that were eligible for statistical analysis. Column 1 displays the gene symbols of the proteins, the protein names are listed in column 2.